A Historical-Controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/day Monotherapy in Subjects with Partial-Onset Seizure (SP902)

Grants and Contracts Details

StatusFinished
Effective start/end date3/23/10 → 9/30/14

Funding

  • Schwarz BioSciences Inc: $11,812.00